1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,190 | 1,290 | 17:11 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.12.25 | GENENTA SCIENCE SPA: Genenta Science Provides Update on CEO Ownership | 225 | GlobeNewswire (Europe) | MILAN and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a clinical-stage gene-therapy company developing hematopoietic stem-cell-based immunotherapies for solid tumors... ► Artikel lesen | |
| 24.11.25 | Aktie von Genenta Science schießt nach Update zu Glioblastom-Studie in die Höhe | 10 | Investing.com Deutsch | ||
| GENENTA SCIENCE Aktie jetzt für 0€ handeln | |||||
| 24.11.25 | GENENTA SCIENCE SPA: Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial | 284 | GlobeNewswire (Europe) | MILAN, Italy and NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a clinical-stage biotechnology company developing a cell-based platform for targeted delivery of therapeutic... ► Artikel lesen | |
| 28.10.25 | Genenta Science S.p.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 27.10.25 | Aktie von Genenta Science stürzt nach 15-Millionen-Dollar-Kapitalerhöhung ab | 13 | Investing.com Deutsch | ||
| 27.10.25 | Genenta Science stock plunges after $15 million ADS offering | 2 | Investing.com | ||
| 27.10.25 | Genenta Science jumps on $15M direct offering | 3 | Seeking Alpha | ||
| 27.10.25 | Genenta Science raises $15 million in ADS offering at $3.50 per share | 4 | Investing.com | ||
| 27.10.25 | GENENTA SCIENCE SPA: Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares | 2 | GlobeNewswire (USA) | ||
| 24.10.25 | Genenta Science Stock Jumps 85% On Strategic Collaboration With Anemocyte | 10 | RTTNews | ||
| 24.10.25 | Genenta Science stock soars on strategic LVV Plasmid DNA collaboration | 5 | Investing.com | ||
| 24.10.25 | Genenta and Anemocyte partner on lentiviral vector plasmid DNA tech | 17 | Investing.com | ||
| 24.10.25 | GENENTA SCIENCE SPA: Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production | 1.561 | GlobeNewswire (Europe) | MILAN, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today... ► Artikel lesen | |
| 10.10.25 | Genenta Science S.p.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 03.10.25 | Genenta Science S.p.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 10.09.25 | Genenta Science S.p.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 01.08.25 | Genenta Science S.p.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 08.05.25 | D.Boral Capital: Genenta Science Announces Participation in the D. Boral Capital Inaugural Global Conference | 249 | Newsfile | Milan, Italy and New York, New York--(Newsfile Corp. - May 8, 2025) - Genenta Science, SpA (NASDAQ: GNTA), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking... ► Artikel lesen | |
| 19.03.25 | GENENTA SCIENCE SPA: Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates | 236 | GlobeNewswire (Europe) | MILAN and NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a €20 million ($21.9 million)... ► Artikel lesen | |
| 09.01.25 | GENENTA SCIENCE SPA: Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing | 692 | GlobeNewswire (Europe) | MILAN and NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that it has strengthened... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VENTYX BIOSCIENCES | 13,785 | +0,40 % | Ventyx Biosciences und BioAge Labs: Tenbagger-Rendite im No Brainer Club! | Mit Ventyx Biosciences feiert der No Brainer Club eine waschechte Tenbagger-Empfehlung: Nach Übernahmegerüchten springt die Aktie heute im regulären Handel zunächst um rund 30% nach oben, bevor sie... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 14,520 | +28,50 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day | MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application... ► Artikel lesen | |
| QIAGEN | 41,100 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| REGENCELL BIOSCIENCE | 42,510 | -19,61 % | Regencell Bioscience is the top performing pharma stock YTD | ||
| ENLIVEN THERAPEUTICS | 24,230 | +56,63 % | Enliven Therapeutics, Inc.: Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones | Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts
ELVN-001... ► Artikel lesen | |
| ALUMIS | 17,550 | -2,06 % | What's Going On With Alumis Stock Thursday? | ||
| EVOTEC | 6,348 | +0,92 % | EQS-News: Evotec SE: Evotec ernennt Dr. Sarah Fakih als EVP, Leiterin Global Communications und Investor Relations | EQS-News: Evotec SE
/ Schlagwort(e): Personalie
Evotec ernennt Dr. Sarah Fakih als EVP, Leiterin Global Communications und Investor Relations
01.01.2026 / 07:30 CET/CEST
Für... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 299,00 | +2,21 % | Praxis Precision Prices $575 Mln Public Offering At $260/shr | ||
| PHATHOM PHARMACEUTICALS | 15,670 | -13,33 % | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| BIONTECH | 85,45 | -0,35 % | BYD gegen Tesla! KI-Profiteure BioNTech und Rio Tinto Partner Aspermont! Aktien für 2026? | Paukenschlag kurz vor Silvester! BYD hat Tesla vom E-Auto-Thron gestoßen. Die Chinesen sind jetzt auch Weltmarktführer bei rein elektrischen Fahrzeugen. Doch die Aktie hat 2025 klar enttäuscht. Ein... ► Artikel lesen | |
| IMMUNEERING | 5,190 | -37,70 % | Immuneering Corporation: Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP | - Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard of care gemcitabine/nab-paclitaxel (GnP) - - Atebimetinib consistently... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 24,300 | +4,38 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects | In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated... ► Artikel lesen | |
| ERASCA | 5,055 | -2,22 % | Erasca stock pulls back after 25% jump, Stifel cites competitor data | ||
| AVIDITY BIOSCIENCES | 72,32 | -0,07 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,720 | -2,88 % | Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week's Business Updates |
GENENTA SCIENCE SPA ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,83 % bei einem Aktienkurs von 1,190 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENENTA SCIENCE SPA ADR finden Sie auf Wallstreet Online.